Sarker Protim, Akhtar Evana, Kuddusi Rakib Ullah, Alam Mohammed Mamun, Haq Md Ahsanul, Hosen Md Biplob, Chanda Bikash Chandra, Haque Farjana, Alam Muntasir, Razzaque Abdur, Rahman Mustafizur, Ahmed Faruque, Kibria Md Golam, Islam Mohammed Zahirul, Ahmed Shehlina, Raqib Rubhana
Infectious Diseases Division, International Centre for Diarrhoeal Disease Research (icddr,b), Dhaka 1212, Bangladesh.
Laboratory Sciences and Services Division, International Centre for Diarrhoeal Disease Research (icddr,b), Dhaka 1212, Bangladesh.
Vaccines (Basel). 2022 Sep 8;10(9):1498. doi: 10.3390/vaccines10091498.
The adaptive immune response is a crucial component of the protective immunity against SARS-CoV-2, generated after infection or vaccination.
We studied antibody titers, neutralizing antibodies and cellular immune responses to four different COVID-19 vaccines, namely Pfizer-BioNTech, Moderna Spikevax, AstraZeneca and Sinopharm vaccines in the Bangladeshi population ( = 1780).
mRNA vaccines Moderna (14,655 ± 11.3) and Pfizer (13,772 ± 11.5) elicited significantly higher anti-Spike (S) antibody titers compared to the Adenovector vaccine AstraZeneca (2443 ± 12.8) and inactivated vaccine Sinopharm (1150 ± 11.2). SARS-CoV-2-specific neutralizing antibodies as well as IFN-γ-secreting lymphocytes were more abundant in Pfizer and Moderna vaccine recipients compared to AstraZeneca and Sinopharm vaccine recipients. Participants previously infected with SARS-CoV-2 exhibited higher post-vaccine immune responses (S-specific and neutralizing antibodies, IFN-γ-secreting cells) compared to uninfected participants. Memory B (B), total CD8T, CD4 central memory (CD4) and T-regulatory (T) cells were more numerous in AstraZeneca vaccine recipients compared to other vaccine recipients. Plasmablasts, B-regulatory (B) and CD4 effector (CD4) cells were more numerous in mRNA vaccine recipients.
mRNA vaccines generated a higher antibody response, while a differential cellular response was observed for different vaccine types, suggesting that both cellular and humoral responses are important in immune monitoring of different types of vaccines.
适应性免疫反应是感染或接种疫苗后产生的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的保护性免疫的关键组成部分。
我们在孟加拉国人群（n = 1780）中研究了对四种不同的2019冠状病毒病（COVID-19）疫苗，即辉瑞-BioNTech疫苗、莫德纳Spikevax疫苗、阿斯利康疫苗和国药疫苗的抗体滴度、中和抗体及细胞免疫反应。
与腺病毒载体疫苗阿斯利康（2443±12.8）和灭活疫苗国药（1150±11.2）相比，信使核糖核酸（mRNA）疫苗莫德纳（14,655±11.3）和辉瑞（13,772±11.5）引发的抗刺突（S）抗体滴度显著更高。与阿斯利康和国药疫苗接种者相比，辉瑞和莫德纳疫苗接种者中SARS-CoV-2特异性中和抗体以及分泌γ干扰素（IFN-γ）的淋巴细胞更为丰富。与未感染的参与者相比，先前感染过SARS-CoV-2的参与者在接种疫苗后表现出更高的免疫反应（S特异性和中和抗体、分泌IFN-γ的细胞）。与其他疫苗接种者相比，阿斯利康疫苗接种者中的记忆B（B）细胞、总CD8T细胞、CD4中央记忆（CD4）细胞和调节性T（T）细胞更多。浆母细胞、调节性B（B）细胞和CD4效应（CD4）细胞在mRNA疫苗接种者中更多。
mRNA疫苗产生了更高的抗体反应，而不同类型疫苗的细胞反应存在差异，这表明细胞和体液反应在不同类型疫苗的免疫监测中都很重要。
Zotero 插件
